A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA.

Category Primary study
Registry of TrialsClinical Trials Peruvian Registry
Year 2023
This article has no abstract
Epistemonikos ID: df3ef9c887fd17e61431a0c38ed700e146f51602
First added on: Apr 12, 2025